Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Der Internist|March 20, 2015
[Acute myeloid leukemia]K Döhner, P Paschka, H Döhner
Journal of Leukocyte Biology|April 26, 2003
Imatinib restores expression of CD62L in BCR-ABL-positive cellsS Fruehauf, J Topaly, M Schad, et al.
Leukemia|June 25, 2011
Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroupsS C Lück, A C Russ, U Botzenhardt, et al.
Leukemia|November 9, 2000
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probesS Saussele, A Weisser, M C Müller, et al.
Leukemia|September 2, 2005
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance developmentA Burchert, Y Wang, D Cai, et al.
British Journal of Cancer|April 23, 2005
Lack of clinical efficacy of imatinib in metastatic melanomaS Ugurel, R Hildenbrand, A Zimpfer, et al.
Leukemia|August 30, 2002
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alphaK Merx, M C Müller, S Kreil, et al.
Leukemia|September 13, 2003
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remissionP Paschka, M C Müller, K Merx, et al.
Leukemia|February 1, 2017
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failureM Wattad, D Weber, K Döhner, et al.
Leukemia|June 24, 2017
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemiaV I Gaidzik, D Weber, P Paschka, et al.
Pageof 2